BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36251440)

  • 1. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
    Soscia R; Della Starza I; De Novi LA; Ilari C; Ansuinelli M; Cavalli M; Bellomarino V; Cafforio L; Di Trani M; Cazzaniga G; Fazio G; Santoro A; Salemi D; Spinelli O; Tosi M; Terragna C; Robustelli V; Bellissimo T; Colafigli G; Breccia M; Chiaretti S; Di Rocco A; Martelli M; Guarini A; Del Giudice I; Foà R
    Hematol Oncol; 2023 Feb; 41(1):50-60. PubMed ID: 36251440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-free circulating tumor DNA in colorectal cancer: a proof of concept with simplified methodology.
    Bosque J; Guirao C; Ferrández A; Suarez N; Castillejo MI; Anguita D; Pamies M; Moya A; Soto JL; Gallego Plazas J
    Clin Transl Oncol; 2022 Oct; 24(10):1924-1931. PubMed ID: 35499600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.
    Huang RSP; Xiao J; Pavlick DC; Guo C; Yang L; Jin DX; Fendler B; Severson E; Killian JK; Hiemenz M; Duncan D; Lin DI; Dennis L; Aiyer A; Gjoerup O; Oxnard G; Venstrom J; Elvin J; Ramkissoon SH; Ross JS
    Clin Chem; 2021 Nov; 67(11):1554-1566. PubMed ID: 34626187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-free DNA - Minimally invasive marker of hematological malignancies.
    Kubaczkova V; Vrabel D; Sedlarikova L; Besse L; Sevcikova S
    Eur J Haematol; 2017 Oct; 99(4):291-299. PubMed ID: 28692178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.
    Lee JS; Kim M; Seong MW; Kim HS; Lee YK; Kang HJ
    Clin Chem Lab Med; 2020 Mar; 58(4):527-532. PubMed ID: 31874093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
    Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.
    Nesic M; Bødker JS; Terp SK; Dybkær K
    Biomed Res Int; 2021; 2021():5585148. PubMed ID: 34307658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
    Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
    Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimized (Pre) Analytical Conditions and Workflow for Droplet Digital PCR Analysis of Cell-Free DNA from Patients with Suspected Lung Carcinoma.
    de Kock R; Deiman B; Kraaijvanger R; Scharnhorst V
    J Mol Diagn; 2019 Sep; 21(5):895-902. PubMed ID: 31229652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of
    Kloten V; Rüchel N; Brüchle NO; Gasthaus J; Freudenmacher N; Steib F; Mijnes J; Eschenbruch J; Binnebösel M; Knüchel R; Dahl E
    Oncotarget; 2017 Oct; 8(49):86253-86263. PubMed ID: 29156792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
    Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA.
    Danesi R; Lo YMD; Oellerich M; Beck J; Galbiati S; Re MD; Lianidou E; Neumaier M; van Schaik RHN
    Clin Chim Acta; 2021 Sep; 520():168-171. PubMed ID: 34081934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood.
    Kresse SH; Brandt-Winge S; Pharo H; Flatin BTB; Jeanmougin M; Vedeld HM; Lind GE
    Clin Epigenetics; 2023 Sep; 15(1):151. PubMed ID: 37710283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a Protocol for Isolating Cell-free DNA From Cerebrospinal Fluid.
    Song HH; Park H; Cho D; Bang HI; Oh HJ; Kim J
    Ann Lab Med; 2024 May; 44(3):294-298. PubMed ID: 38151854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
    Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
    Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
    van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
    Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.